NCT01994850View on ClinicalTrials.gov

Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

August 31, 2017

Study Completion Date

January 31, 2019

Conditions
CD30 Positive Primary Mediastinal Large B-cell LymphomaCD30-Positive Diffuse Large B-Cell LymphomaCD30-Positive Gray Zone Lymphoma
Interventions
DRUG

brentuximab vedotin

Trade name: Adcetris

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01994850 - Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients | Biotech Hunter | Biotech Hunter